Human Pluripotent Stem Cell‐Derived Mesenchymal Stem Cells Prevent Allergic Airway Inflammation in Mice

Abstract

We previously found that mesenchymal stem cells (MSCs) derived from human-induced pluripotent stem cells (iPSCs) exerted immunomodulatory effects on Th2-mediated allergic rhinitis in vitro. However, their contribution to the asthma and allergic rhinitis in animal models remains unclear. In this study, we developed a mouse model of ovalbumin (OVA)-induced allergic inflammation in both the upper and lower airways and evaluated the effects of the systemic administration of human iPSC-MSCs and bone marrow-derived MSCs (BM-MSCs) on allergic inflammation. Our results showed that treatments with both the iPSC-MSCs and BM-MSCs before the challenge phase protected the animals from the majority of allergy-specific pathological changes. This protection included an inhibition of inflammatory cell infiltration and mucus production in the lung, a reduction in eosinophil infiltration in the nose, and a decrease in inflammatory cell infiltration in both the bronchoalveolar and nasal lavage fluids. In addition, treatment with iPSC-MSCs or BM-MSCs before the challenge phase resulted in reduced serum levels of Th2 immunoglobulins (e.g., IgE) and decreased levels of Th2 cytokines including interleukin (IL)-4, IL-5, or IL-13 in the bronchoalveolar and/or nasal lavage fluids. Similar therapeutic effects were observed when the animals were pretreated with human iPSC-MSCs before the sensitization phase. These data suggest that iPSC-MSCs may be used as an alternative strategy to adult MSCs in the treatment of asthma and allergic rhinitis.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 41

1. 1.

   Singer NG, Caplan AI. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol. 2011;6:457-478.

   Not in our library10.1146/annurev-pathol-011110-130230

2. 2.

   Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-736.

   Not in our library10.1038/nri2395

3. 3.

   Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol. 2007;28:219-226.

   Not in our library10.1016/j.it.2007.03.001

4. 4.

   Keating A. Mesenchymal stromal cells: New directions. Cell Stem Cell. 2012;10:709-716.

   Not in our library10.1016/j.stem.2012.05.015

5. 5.
   Aging and Replicative Senescence Have Related Effects on Human Stem and Progenitor Cells · 2009

   No notice
6. 6.

   Crisostomo PR, Wang M, Wairiuko GM, et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock. 2006;26:575-580.

   Not in our library10.1097/01.shk.0000235087.45798.93

7. 7.
   Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells · 2008

   No notice
8. 8.

   Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004;109:1615-1622.

   Not in our library10.1161/01.cir.0000124476.32871.e3

9. 9.

   Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res. 2008;314:1937-1944.

   Not in our library10.1016/j.yexcr.2008.03.006

10. 10.

    Lian Q, Zhang Y, Zhang J, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121:1113-1123.

    Not in our library10.1161/circulationaha.109.898312

11. 11.

    Giuliani M, Oudrhiri N, Noman ZM, et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood. 2011;118:3254-3262.

    Not in our library10.1182/blood-2010-12-325324

12. 12.

    Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, Ga(2)Len And Allergen) Allergy. 2008;63(suppl 86):8-160.

    Not in our library10.1111/j.1398-9995.2007.01620.x

13. 13.

    Eder W, Ege MJ, von ME. The asthma epidemic. N Engl J Med. 2006;355:2226-2235.

    Not in our library10.1056/nejmra054308

14. 14.

    Gerez IF, Lee BW, van Bever HP, et al. Allergies in Asia: Differences in prevalence and management compared with western populations. Expert Rev Clin Immunol. 2010;6:279-289.

    Not in our library10.1586/eci.09.82

15. 15.

    Compalati E, Ridolo E, Passalacqua G, et al. The link between allergic rhinitis and asthma: The united airways disease. Expert Rev Clin Immunol. 2010;6:413-423.

    Not in our library10.1586/eci.10.15

16. 16.

    Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454:445-454.

    Not in our library10.1038/nature07204

17. 17.

    Goodwin M, Sueblinvong V, Eisenhauer P, et al. Bone marrow-derived mesenchymal stromal cells inhibit th2-mediated allergic airways inflammation in mice. Stem Cells. 2011;29:1137-1148.

    Not in our library10.1002/stem.656

18. 18.

    Nemeth K, Keane-Myers A, Brown JM, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA. 2010;107:5652-5657.

    Not in our library10.1073/pnas.0910720107

19. 19.

    Bonfield TL, Koloze M, Lennon DP, et al. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol. 2010;299:L760-L770.

    Not in our library10.1152/ajplung.00182.2009

20. 20.
    Defining human mesenchymal stem cell efficacy <it>in vivo</it> · 2010

    Not checked
21. 21.

    Cho KS, Roh HJ. Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases. Curr Stem Cell Res Ther. 2010;5:111-115.

    Not in our library10.2174/157488810791268681

22. 22.

    Cho KS, Park HK, Park HY, et al. IFATS collection: Immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells. 2009;27:259-265.

    Not in our library10.1634/stemcells.2008-0283

23. 23.

    Fu QL, Chow YY, Sun SJ, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy. 2012;67:1215-1222.

    Not in our library10.1111/j.1398-9995.2012.02875.x

24. 24.

    Zhang J, Lian Q, Zhu G, et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell. 2011;8:31-45.

    Not in our library10.1016/j.stem.2010.12.002

25. 25.

    Lian Q, Lye E, Suan YK, et al. Derivation of clinically compliant MSCs from CD105+. Stem Cells. 2007;25:425-436.

    Not in our library10.1634/stemcells.2006-0420

26. 26.

    Hellings PW, Hessel EM, Van Den OordJJ, et al. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy. 2001;31:782-790.

    Not in our library10.1046/j.1365-2222.2001.01081.x

27. 27.

    Yokota E, Kuyama S, Ogawa M, et al. Substance P is involved in the effect of histamine H3 receptor agonist, Sch 50971 on nasal allergic symptoms in mice. Int Immunopharmacol. 2008;8:1083-1088.

    Not in our library10.1016/j.intimp.2008.03.018

28. 28.

    Kang JH, Kim BS, Uhm TG, et al. Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses. Am J Respir Crit Care Med. 2009;179:875-882.

    Not in our library10.1164/rccm.200806-893oc

29. 29.

    Tournoy KG, Kips JC, Schou C, et al. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy. 2000;30:79-85.

    Not in our library10.1046/j.1365-2222.2000.00772.x

30. 30.

    Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2011;66:523-531.

    Not in our library10.1111/j.1398-9995.2010.02509.x

31. 31.

    Firinci F, Karaman M, Baran Y, et al. Mesenchymal stem cells ameliorate the histopathological changes in a murine model of chronic asthma. Int Immunopharmacol. 2011;11:1120-1126.

    Not in our library10.1016/j.intimp.2011.03.009

32. 32.

    Su WR, Zhang QZ, Shi SH, et al. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells. 2011;29:1849-1860.

    Not in our library10.1002/stem.738

33. 33.

    Broide DH, Finkelman F, Bochner BS, et al. Advances in mechanisms of asthma, allergy, and immunology in 2010. J Allergy Clin Immunol. 2011;127:689-695.

    Not in our library10.1016/j.jaci.2011.01.027

34. 34.

    Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105:2821-2827.

    Not in our library10.1182/blood-2004-09-3696

35. 35.

    Brown JM, Nemeth K, Kushnir-Sukhov NM, et al. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011;41:526-534.

    Not in our library10.1111/j.1365-2222.2010.03685.x

36. 36.

    Zhang Y, Liao S, Yang M, et al. Improved cell survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension. Cell Transplant. 2012.

    Not in our library10.3727/096368912x653020

37. 37.

    Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27:1421-1432.

    Not in our library10.1002/stem.68

38. 38.

    Zhou K, Zhang H, Jin O, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008;5:417-424.

    Not in our library10.1038/cmi.2008.52

39. 39.

    Gruenloh W, Kambal A, Sondergaard C, et al. Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Tissue Eng Part A. 2011;17:1517-1525.

    Not in our library10.1089/ten.tea.2010.0460

40. 40.

    Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011;471:68-73.

    Not in our library10.1038/nature09798

Cited by papers we hold 10

• AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages · 2022
  No notice
• Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy · 2020
  No notice
• Application of Stem Cell-Derived Extracellular Vesicles in Allergic Airway Diseases · 2020
  Not checked
• Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p · 2020
  Not checked
• MSC Based Therapies—New Perspectives for the Injured Lung · 2020
  No notice
• Mesenchymal stem cells: amazing remedies for bone and cartilage defects · 2020
  No notice
• Stem Cell-Derived Extracellular Vesicles as Immunomodulatory Therapeutics · 2019
  No notice
• Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials · 2016
  No notice
• Mesenchymal stem cells and immunomodulation: current status and future prospects · 2016
  No notice
• Epigenetic Rejuvenation of Mesenchymal Stromal Cells Derived from Induced Pluripotent Stem Cells · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.